| Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. | |
| | |
MedLine Citation:
|
PMID: 16197656 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Histamine receptor activation and degranulation of mast cells are the mechanisms by which the ocular itching, hyperemia, chemosis, eyelid swelling, and tearing of seasonal allergic conjunctivitis are induced. Some of the topical solutions available as anti-allergy therapies are intended to interfere with these mechanisms, and the body of research regarding the capabilities of these therapeutic molecules continues to expand. OBJECTIVE: To review the currently available literature regarding one topical ophthalmic anti-allergy agent, olopatadine (Patanol), and its anti-histaminic and mast cell stabilizing actions, both in pre-clinical and clinical settings. DESIGN AND METHODS: Relevant research of laboratory, animal model, and clinical trial studies performed using olopatadine was reviewed. MEDLINE literature searches were conducted and supplemented by additional reports which furthered relevant discussion or were necessary to verify the information resulting from original searches. RESULTS: Olopatadine demonstrates unique properties both pre-clinically and clinically which differentiate it from other therapeutic molecules in its class of dual action mast cell stabilizer/anti-histamine. Its non-perturbation of cell membranes, human conjunctival mast cell stabilization in vivo and in vitro, and superior efficacy as compared to other topical anti-allergic medications including mast cell stabilizers, anti-histamines, and dual action agents, all contribute to olopatadine's profile. CONCLUSIONS: Peer-reviewed literature suggests that olopatadine is clinically superior to the other anti-allergic molecules because of its strong anti-histaminic qualities and its unique ocular mast cell stabilizing properties. |
| | |
Authors:
|
Lanny J Rosenwasser; Terrence O'Brien; Jonathan Weyne |
Related Documents
:
|
2169856 - Local and systemic effects of an acute inflammation on eicosanoid generation capacity o... 3989796 - An assessment of mast-cell deficient mice (w/wv) as a model system to study the role of... 8651016 - Pruritogenic effects of mitogen-stimulated peripheral blood mononuclear cells in atopic... 11119556 - Tick salivary gland extract inhibits killing of borrelia afzelii spirochetes by mouse m... 12242076 - Distinctive response of thyroid-infiltrating mononuclear cells to b cell activation thr... 20036516 - Study of lymphocyte subpopulations in bone marrow in a model of protein-energy malnutri... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Review |
Journal Detail:
|
Title: Current medical research and opinion Volume: 21 ISSN: 0300-7995 ISO Abbreviation: Curr Med Res Opin Publication Date: 2005 Sep |
Date Detail:
|
Created Date: 2005-10-03 Completed Date: 2005-10-28 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0351014 Medline TA: Curr Med Res Opin Country: England |
Other Details:
|
Languages: eng Pagination: 1377-87 Citation Subset: IM |
Affiliation:
|
National Jewish Medical and Research Center, Denver, CO, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Allergic Agents
/
administration & dosage,
pharmacology,
therapeutic use* Dibenzoxepins / administration & dosage, pharmacology, therapeutic use* Drug Evaluation, Preclinical Histamine H1 Antagonists / administration & dosage, pharmacology, therapeutic use* Humans Mast Cells / drug effects*, metabolism Ophthalmic Solutions Placebo Effect Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Allergic Agents; 0/Dibenzoxepins; 0/Histamine H1 Antagonists; 0/Ophthalmic Solutions; 113806-05-6/olopatadine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depres...
Next Document: Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Ach...